Table 1 Demographics and clinicopathologic characteristics of patients with glioma
From: ARL3 is downregulated and acts as a prognostic biomarker in glioma
| Characteristic | Primary cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
| CGGA (n = 310) | Gravendeel (n = 211) | TCGA (n = 598) | ||||
| No. of patients | % | No. of patients | % | No. of patients | % | |
| ARL3 level | ||||||
| Median | 13.402 | 6.658 | 10.623 | |||
| Range | 2.762–28.522 | 5.591–8.921 | 8.787–13.299 | |||
| Gender | ||||||
| Male | 195 | 62.903 | 146 | 69.194 | 350 | 58.528 |
| Female | 115 | 37.097 | 65 | 30.806 | 248 | 41.472 |
| Age, years | ||||||
| Median | 43 | 50 | 47 | |||
| Range | 8–81 | 14–81 | 14–89 | |||
| WHO grade | ||||||
| Grade II | 105 | 33.871 | 21 | 9.953 | 211 | 35.284 |
| Grade III | 67 | 21.613 | 66 | 31.280 | 239 | 39.967 |
| Grade IV | 138 | 44.516 | 124 | 58.768 | 148 | 24.749 |
| IDH status | ||||||
| Wild type | 146 | 47.097 | 131 | 62.085 | 222 | 37.124 |
| Mutant | 164 | 52.903 | 80 | 37.915 | 376 | 62.876 |
